The first prospective, multisite evaluation of Oregon’s state-regulated psilocybin program has reported improvements in mental health symptoms, well-being, and life satisfaction during the three months after supervised services.
The findings are encouraging.
They do not prove that psilocybin caused the improvements.
Published in JAMA Network Open, the study followed 346 adults who received psilocybin services at 24 of Oregon’s 26 actively licensed service centers. Participants completed assessments before their session and again after one week, one month, and three months.
At three months, the proportion of participants reporting moderate-to-severe depression, anxiety, or post-traumatic stress symptoms was substantially lower than at baseline. Most participants reported benefiting from the experience, and serious adverse reactions requiring medical attention were uncommon.
The study also identified clinically important concerns. Four participants experienced serious behavioral reactions. Some adverse effects emerged after the administration day and were not captured by facilitator reports. The people using Oregon’s services were disproportionately white, highly educated, and affluent, raising questions about access and generalizability.
This is not a clinical trial of psilocybin for a diagnosed psychiatric disorder. It is a real-world evaluation of a state-regulated wellness model.
That distinction is central to understanding what the study can and cannot tell us.
What Oregon’s Program Actually Provides
Oregon’s psilocybin system differs from both conventional medical care and unsupervised psychedelic use.
Adults aged 21 and older may receive psilocybin services for a range of reasons. They do not need a psychiatric diagnosis or a prescription. Psilocybin products are manufactured, tested, and tracked within the state system, then consumed at a licensed service center under the supervision of a licensed facilitator. Take-home doses are not permitted.
Services must include at least one preparation session and a directly observed administration session. Integration afterward is encouraged but optional.
Facilitators complete state-required education and a practicum, but they are not required to be licensed mental health clinicians. Their role is to support the participant within the boundaries established by Oregon regulations. Diagnosis, psychotherapy, medication management, and treatment of medical or psychiatric complications may fall outside their scope.
This makes Oregon an important natural laboratory. It tests what happens when supervised psilocybin is offered through a community-based regulatory system rather than a pharmaceutical trial or specialist psychiatric clinic.
By 2026, more than 20,000 people had reportedly received services through the program. That scale makes systematic outcome collection essential.
What the OPEN Study Measured
The Open Psychedelic Evaluation Nexus, or OPEN, enrolled clients between November 2024 and March 2026. Follow-up for the current analysis continued through June 2026.
The study included 346 participants supervised by 83 facilitators at 24 licensed centers. Retention was high:
93.1 percent completed the one-week assessment
92.8 percent completed the one-month assessment
90.2 percent completed the three-month assessment
Participants had an average age of 49.5 years, and 52.5 percent were women. Nearly 44 percent had never previously used a psychedelic.
Researchers assessed depression, anxiety, PTSD symptoms, mental well-being, life satisfaction, satisfaction with services, perceived benefits and harms, and adverse reactions. Facilitators reported the administered dose and safety events observed during the session.
The average psilocybin dose was 31.9 milligrams, with doses ranging from 2 to 50 milligrams. Most participants received individual sessions, while 18.5 percent participated in group administration.
Nearly every participant reported attending at least one preparation session, with an average of 2.4 sessions. At one month, 90.6 percent reported attending at least one integration session, with an average of 1.9 sessions.
These details matter. The study evaluated psilocybin within a structured service model, not psilocybin alone.
Mental Health Symptoms Declined Over Three Months
The most visible results involved changes in depression, anxiety, and PTSD symptom scores.
The proportion of participants with moderate-to-severe depression symptoms fell from 42.2 percent at baseline to 10.6 percent after one month and 16.5 percent after three months.
Moderate-to-severe anxiety symptoms declined from 45.1 percent at baseline to 11.9 percent after one month and 13.2 percent after three months.
Moderate-to-severe PTSD symptoms declined from 48 percent at baseline to 19.4 percent after one month and 16.8 percent after three months.
Participants also reported higher well-being and life satisfaction. The proportion who described themselves as somewhat or very satisfied with life increased from 63 percent at baseline to 83.4 percent after one month and 82.3 percent after three months.
At one month, 92.2 percent said they had benefited from the experience. More than 81 percent reported that their goals had been met, and 58.6 percent ranked the experience among the ten most meaningful of their lives.
These changes are substantial enough to deserve attention.
They should not be interpreted as proof of treatment efficacy.
This Was an Observational Study, Not a Controlled Trial
The study used a prospective, single-arm observational design. Everyone chose to receive psilocybin services, and there was no placebo, active comparator, or matched group that did not receive services.
Without a control group, the researchers could not determine how much of the observed change resulted from psilocybin.
Other possible influences include expectation, preparation, the relationship with the facilitator, integration, time, concurrent treatment, social support, regression toward the mean, and the personal significance participants assigned to the event.
The study also measured changes across the entire cohort rather than limiting the analysis to people with confirmed psychiatric diagnoses. Curiosity was the most common reason for seeking services, reported by 74.3 percent of participants. Approximately 71.4 percent wanted to improve or change themselves, 64.5 percent wanted to address mental health symptoms, 51.4 percent wanted to process trauma, 29.2 percent cited spiritual reasons, and 19.9 percent cited professional burnout.
Baseline symptom levels were relatively low across the full group, and diagnostic status was unknown. A reduction on a symptom questionnaire does not establish remission from a diagnosed disorder.
The appropriate conclusion is that participants reported meaningful improvements after regulated psilocybin services. The study cannot establish that psilocybin caused those improvements or that the same outcomes would occur in a clinical population.
Serious Reactions Were Uncommon but Clinically Important
Four participants, representing 1.2 percent of the cohort, experienced serious behavioral reactions requiring medical attention.
All four were psychedelic-naive. They had pre-existing mental health vulnerabilities and received doses between 25 and 50 milligrams.
The events included a violent behavioral reaction requiring hospital transport, severe and persistent anxiety, insomnia, worsening depression, emergency department visits, new medication, and thoughts of death or self-harm.
These cases complicate any simple statement that regulated psilocybin services are safe.
The overall frequency of serious reactions was low, but low frequency does not mean low significance. A service model must be capable of identifying vulnerability, responding during a crisis, arranging follow-up care, and learning from events that develop after a client leaves the center.
The cases also demonstrate why meaningfulness cannot be used as a substitute for safety. Three of the four participants still described their experience as highly meaningful, and two reported that their goals had been met.
A psychologically significant experience can also be destabilizing. Practitioners must be able to hold both realities at once.
The Current Reporting Window May Miss Delayed Harm
One of the study’s most consequential findings concerns adverse-event reporting.
Facilitators reported only one of the four serious reactions. For two cases, facilitators recorded no adverse reaction on the administration day even though the participants later reported emergency care or prolonged psychological difficulties.
Oregon’s mandatory reporting system focuses on safety events occurring during services or within a short period afterward. The study authors warned that this approach can underestimate events that appear later, including persistent anxiety, worsening depression, severe insomnia, or suicidal thoughts.
Participant reports illustrate why longitudinal monitoring matters.
At three months, 4.5 percent reported persistent or worsening depression, 2.3 percent reported persistent or worsening anxiety, and 1.9 percent reported new thoughts of dying or suicide. Approximately 1.6 percent reported receiving a new prescription medication related to the experience, while 1.3 percent reported visiting a healthcare professional.
Some participants reported symptoms associated with hallucinogen persisting perception disorder. Ten percent reported these perceptual symptoms at one month and 8.7 percent at three months. Only one participant said the symptoms caused significant distress or disruption, but the finding still warrants continued assessment.
A system that records only what happens in the room will miss part of the safety picture.
Safety Requires Continuity, Not Only Supervision
Oregon’s model requires direct supervision during administration, which addresses many immediate risks. But supervision on the dosing day cannot replace continuity of care.
Delayed problems may emerge after the facilitator-client relationship has formally ended. A participant may experience insomnia, anxiety, depression, interpersonal disruption, or difficulty interpreting the experience. Those concerns may require clinical assessment outside a facilitator’s scope.
Programs therefore need clear pathways that begin with screening for psychiatric and medical vulnerability and identifying the participant’s current providers and sources of support. When the screening process reveals elevated risk, specialist consultation may be necessary before services proceed.
Continuity should also include structured follow-up after administration. Programs need procedures for responding to delayed distress or functional deterioration, including clear escalation protocols for suicidality, mania, psychosis, or persistent perceptual symptoms. Events that occur after the administration day should be documented and reported rather than treated as unrelated simply because they emerged later.
Effective continuity also requires coordination with licensed mental health and medical professionals. Facilitators should know where to refer participants, how to communicate concerns within privacy and consent requirements, and when a situation has moved beyond supportive facilitation.
This does not mean every client requires psychotherapy. It means that a regulated system needs a plan for what happens when supportive facilitation is not enough.
Access Remains Unequal
The OPEN cohort closely resembled the population using Oregon’s program, but that population was not representative of the broader public.
Among participants, 86.7 percent identified as white and 76.6 percent held at least a bachelor’s degree. Approximately 41.2 percent held a master’s or doctoral degree, while 29 percent reported household income above $200,000.
Nearly one-third said the cost created financial strain, even though 81 percent believed the experience was worth the money.
These figures suggest that state-regulated access currently favors people with substantial financial and educational resources. The findings may not generalize to lower-income clients, people with less formal education, or historically marginalized communities.
The access problem is not separate from safety. People with fewer resources may have less access to psychiatric assessment, ongoing therapy, transportation, time away from work, or emergency follow-up. Expanding participation without strengthening these supports could shift risk toward those least able to absorb it.
For policymakers, affordability must be evaluated alongside training standards, product testing, and service-center regulation.
What the Study Means for Facilitator Training
The study offers useful direction for education and professional development.
First, psychedelic-naive clients may require particular attention. All four serious reactions occurred among participants without previous psychedelic experience. This does not prove that psychedelic naivete independently caused the reactions, but it supports careful preparation and conservative risk assessment.
Second, baseline vulnerability matters. Training should help facilitators recognize when trauma symptoms, depression, anxiety, medication use, or limited support may require consultation or referral.
Third, high satisfaction should not be mistaken for complete safety. Ninety-seven percent of participants rated the services as high quality, yet serious and delayed adverse reactions still occurred.
Fourth, adverse-event education must extend beyond acute management. Facilitators need to know what delayed symptoms warrant follow-up, documentation, referral, or emergency intervention.
Finally, scope of practice must remain clear. Facilitators can provide preparation, presence, and integration within their role. They should not diagnose or treat conditions beyond their qualifications. Strong systems make referral a sign of competence, not failure.
Real-World Evidence Can Improve Regulation
The study demonstrates the value of collecting outcomes directly from clients rather than relying exclusively on incident reports filed by providers.
Provider reports capture what is visible during services. Participant follow-up captures what unfolds afterward. Both are necessary.
Future monitoring systems should collect standardized information about dose, preparation, integration, client goals, prior psychedelic experience, psychiatric symptoms, medications, adverse events, healthcare use, and functional outcomes.
They should also follow clients for months rather than days.
Observational data cannot replace randomized trials. It can answer different questions. Clinical trials estimate efficacy under controlled conditions. Real-world studies show how a system performs across diverse centers, facilitators, intentions, and service models.
As Colorado, New Mexico, and other jurisdictions develop psychedelic programs, longitudinal evaluation should be built into implementation from the beginning.
A Promising System Must Be Willing to Measure Its Risks
The Oregon study provides a cautiously encouraging picture.
Most participants reported benefits, high satisfaction, improved well-being, and lower mental health symptom scores. Serious reactions requiring medical attention were uncommon, and no participants reported unwanted physical or sexual contact from facilitators.
The study also shows that regulation does not eliminate risk. Some adverse reactions emerged after the session, some were missed by facilitator reporting, and the people accessing services were not economically or demographically representative.
The correct response is neither to dismiss the program nor to declare its effectiveness proven.
It is to strengthen the parts of the system that real-world evidence has made visible.
That means better longitudinal monitoring, clearer referral pathways, continued facilitator support, transparent adverse-event reporting, and serious attention to affordability and access.
Oregon has moved psychedelic policy from theory into practice. The next measure of its success will be whether the program can learn from both the people who benefited and the smaller number who needed more care than the system initially provided.
Sources
JAMA Network Open: Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services
Oregon Health Authority: Oregon Psilocybin Services Fact Sheet
Oregon Secretary of State: Psilocybin Services Administrative Rules
This article is for educational purposes and does not constitute medical or legal advice. Psilocybin remains legally restricted in many jurisdictions and should not be used as a substitute for licensed medical or mental health care.
